Results and outcome of intermittent imatinib (ON/OFF schedule) in children and adolescents with chronic myeloid leukaemia
The treatment of children and adolescents with chronic myeloid leukaemia (CML) is based on that of adult patients,
with tyrosine kinase inhibitors (TKIs) being the mainstay and first-line therapies. TKIs have been demonstrated to be
highly effective in CML, with life expectancy in patients treated with TKI similar to that of the age-matched healthy